New Genes: Crop gene-editor Calyxt files for a $50 million IPO
Calyxt, a developer of gene-edited crop traits spun out of Cellectis, filed on Friday with the SEC to raise up to $50 million in an initial public offering.
The New Brighton, MN-based company was founded in 2010. It has not disclosed a proposed ticker or exchange. Calyxt filed confidentially on May 15, 2017. Citi, Credit Suisse and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
The article New Genes: Crop gene-editor Calyxt files for a $50 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.